The Chilean startup, out of Y Combinator's Summer 2021 batch, sends nurses and lab technicians to your home the way a ride app sends drivers. It has served more than 300,000 patients - and it reached break-even in Mexico after a hard reset.
The pitch started as a complaint. In 2021, three engineers in Santiago noticed you could get a burger to your door in half an hour but couldn't get a blood test without a morning of fasting, traffic and a waiting-room magazine from 2014. So they built the thing they wanted: an app where you tap a few times and, a couple of hours later, a nurse is at your kitchen table with a needle and a cooler bag. That is Examedi, and the shorthand its founders use is blunt - "Uber, but for medical lab work."
Examedi came out of Y Combinator's Summer 2021 batch, born in the thick of the pandemic when the immediate job was delivering COVID PCR tests to people who couldn't or shouldn't leave home. Plenty of companies were spun up for that exact moment. Most of them ended when the moment did. Examedi did something more interesting: it kept the hard part - a network that reliably gets a trained person to a real address on time - and swapped out the cargo.
Book on the app or website, pick a service and a time, and Examedi routes a nurse or lab technician to you. They draw the blood or collect the sample; a partner laboratory runs the analysis; results and the insurance paperwork come back through the platform. In Chile that includes automatic reimbursement through FONASA and the private ISAPRE system, which removes the part of medical admin everyone hates. The company says the at-home version can run up to 70% cheaper than walking into a clinic.
Blood work was the wedge, not the ceiling. Over time the same visit became a platform. Examedi added flu shots and injections, then 24/7 telemedicine that connects a patient with an available doctor without an appointment. In 2023 it launched Assisted Telemedicine, a neat hybrid: a health professional is physically in the room to examine and guide the patient while a remote doctor supervises and issues the diagnosis. Nutrition, kinesiology, therapeutic massage and mental health followed. The nurse at your door stopped being a one-trick errand and became a doorway to the rest of the catalog.
On the consumer side, the users are ordinary families in Chile and Mexico - people who need routine labs, a vaccine, a sick kid seen quickly, or an elderly relative who shouldn't be dragged across a city for a 15-minute draw. The 4.8-star rating across 300,000-plus patients is the tell: this is a repeat-use utility, not a one-time novelty. There is also a quieter B2B side, where insurers and health providers tap into Examedi's logistics and telemedicine layer rather than build their own last mile.
It is tempting to file Examedi under telemedicine or under lab testing. It fits neither cleanly. The competitors on one side are traditional clinics and big lab chains; on the other are the app-only telehealth players. What Examedi owns that neither group does is the physical routing problem - matching the right clinician to the right home at the right time, at a price that works. The founders were engineers first, and they looked at a doctor's visit and saw a scheduling, routing and payments problem. That framing is the difference between a website and a company.
Examedi raised roughly $3.5M in seed money, then a $17M Series A led by General Catalyst in 2022, capital that funded the expansion from testing into a broader marketplace and a push into Mexico and a presence in Miami. Then the healthtech weather turned. In late 2025 the company raised a smaller $750K round led by Platanus Ventures, at a reset valuation about 80% below the Series A peak, as General Catalyst exited. On paper that reads like a fall. In practice, the same period is when Examedi reached break-even in Mexico - the number that actually decides whether a company gets to keep existing.
The revenue tells its own story: reports put Examedi around $14.9M-$15M in annual revenue with a team that has hovered between roughly 50 and 100 people depending on the year and the round. Leadership shifted too. Mariano Werner - a Stanford MBA who came through BCG and Lemontech - stepped in as CEO in October 2024, while co-founder Ian Lee moved to Chairman before he and two other founders transitioned out of day-to-day roles in early 2025.
Fast Company named Examedi one of 2024's most innovative companies in Latin America, which is a fair read of where it sits: not the first company to imagine at-home diagnostics, but one of the few in the region turning it into durable infrastructure rather than a pandemic footnote. The comparison people reach for in the US is Getlabs; the difference is that Examedi is building for markets where clinic access, cost and trust are bigger frictions, and where "the lab comes to you" is less a luxury than a genuine unlock.
The through-line is unglamorous and that is the point. Examedi did not win a slogan contest. It showed up, on time, at the front door, and kept doing it until 300,000 people had let a stranger with a needle into their homes and given the experience 4.8 stars. In healthcare, reliability is the marketing.